Figure 4.Cellular aggregation in RSCL and RRCL treated with rituximab. Rituximab enhances cellular aggregation in both ICAM-1 high expressed RSCL and ICAM-1 low expressed RRCL.
Figure 4 — The adhesion molecule ICAM-1 in diffuse large B-cell lymphoma post-rituximab era: relationship with prognostic importance and rituximab resistance | Aging
